Artgen Biotech PJSC Statistics

Total Valuation

Artgen Biotech PJSC has a market cap or net worth of RUB 4.29 billion. The enterprise value is 4.94 billion.

Market Cap	4.29B
Enterprise Value	4.94B

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Artgen Biotech PJSC has 71.99 million shares outstanding. The number of shares has decreased by -0.41% in one year.

Current Share Class	n/a
Shares Outstanding	71.99M
Shares Change (YoY)	-0.41%
Shares Change (QoQ)	-33.44%
Owned by Insiders (%)	46.62%
Owned by Institutions (%)	0.14%
Float	n/a

Valuation Ratios

The trailing PE ratio is 20.02.

PE Ratio	20.02
Forward PE	n/a
PS Ratio	2.95
PB Ratio	10.17
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.59, with an EV/FCF ratio of 16.57.

EV / Earnings	22.43
EV / Sales	3.31
EV / EBITDA	12.59
EV / EBIT	15.16
EV / FCF	16.57

Financial Position

The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.83.

Current Ratio	1.88
Quick Ratio	1.01
Debt / Equity	0.83
Debt / EBITDA	1.93
Debt / FCF	2.65
Interest Coverage	6.51

Financial Efficiency

Return on equity (ROE) is 29.67% and return on invested capital (ROIC) is 12.72%.

Return on Equity (ROE)	29.67%
Return on Assets (ROA)	8.81%
Return on Capital (ROIC)	12.72%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.61
Inventory Turnover	1.81

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +55.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+55.78%
50-Day Moving Average	66.85
200-Day Moving Average	91.44
Relative Strength Index (RSI)	40.78
Average Volume (20 Days)	234,009

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Artgen Biotech PJSC had revenue of RUB 1.49 billion and earned 220.07 million in profits. Earnings per share was 2.97.

Revenue	1.49B
Gross Profit	1.07B
Operating Income	342.72M
Pretax Income	269.26M
Net Income	220.07M
EBITDA	383.30M
EBIT	342.72M
Earnings Per Share (EPS)	2.97

Full Income Statement

Balance Sheet

The company has 394.93 million in cash and 789.60 million in debt, giving a net cash position of -394.67 million or -5.48 per share.

Cash & Cash Equivalents	394.93M
Total Debt	789.60M
Net Cash	-394.67M
Net Cash Per Share	-5.48
Equity (Book Value)	953.87M
Book Value Per Share	5.85
Working Capital	475.69M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 495.43 million and capital expenditures -197.47 million, giving a free cash flow of 297.96 million.

Operating Cash Flow	495.43M
Capital Expenditures	-197.47M
Free Cash Flow	297.96M
FCF Per Share	4.14

Full Cash Flow Statement

Margins

Gross margin is 71.57%, with operating and profit margins of 22.96% and 14.74%.

Gross Margin	71.57%
Operating Margin	22.96%
Pretax Margin	18.04%
Profit Margin	14.74%
EBITDA Margin	25.68%
EBIT Margin	22.96%
FCF Margin	19.96%

Dividends & Yields

Artgen Biotech PJSC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.41%
Shareholder Yield	0.41%
Earnings Yield	4.99%
FCF Yield	6.95%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Artgen Biotech PJSC has an Altman Z-Score of 1.45. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.45
Piotroski F-Score	n/a